Predictors of cognitive impairment in newly diagnosed Parkinson's disease with normal cognition at baseline: A 5-year cohort study

被引:9
作者
Chen, Jing [1 ]
Zhao, Danhua [1 ]
Wang, Qi [1 ]
Chen, Junyi [1 ]
Bai, Chaobo [1 ]
Li, Yuan [1 ]
Guo, Xintong [1 ]
Chen, Baoyu [1 ]
Zhang, Lin [2 ]
Yuan, Junliang [1 ]
机构
[1] Peking Univ, Peking Univ Sixth Hosp, Natl Clin Res Ctr Mental Disorders, Inst Mental Hlth,NHC Key Lab Mental Hlth,Dept Neur, Beijing, Peoples R China
[2] UC Davis Deep Brain Stimulat DBS, Dept Neurol & Neurol Surg, Sacramento, CA USA
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
基金
中国国家自然科学基金;
关键词
Parkinson's disease; mild cognitive impairment; dementia; Montreal cognitive assessment; neuropsychological test; LONGITUDINAL ANALYSIS; BIOMARKERS; DEMENTIA; DECLINE; CRITERIA; RISK;
D O I
10.3389/fnagi.2023.1142558
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background and objectiveCognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson's disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years). MethodsWe evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson's Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein (APO) E status, beta-glucocerebrosidase (GBA) mutation status, cerebrospinal fluid findings, and dopamine transporter imaging results. Using a diagnosis of CI (combined mild cognitive impairment and dementia) developed during the 5-year follow-up as outcome measures, we assessed the predictive values of baseline clinical variables and biomarkers. We also constructed a predictive model for the diagnosis of CI using logistic regression analysis. ResultsA total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and APOE status were associated with the development of CI. Predictive accuracy of CI using age alone improved by the addition of clinical variables and biomarkers (current diagnosis of hypertension, baseline MoCA scores, and MDS-UPDRS III scores, APOE status; AUC 0.80 [95% CI 0.74-0.86] vs. 0.71 [0.64-0.77], p = 0.008). Cognitive domains that had higher frequencies of impairment were found in verbal memory (12.6 vs. 16.8%) and attention/processing speed (12.7 vs. 16.9%), however, no significant difference in the prevalence of CI at annual follow-up was found during the 5-year follow-up in NDPD patients. ConclusionIn NDPD, the development of CI during the 5-year follow-up can be predicted with good accuracy using a model combining age, current diagnosis of hypertension, baseline MoCA scores, MDS-UPDRS III scores, and APOE status. Our study underscores the need for the earlier identification of CI in NDPD patients in our clinical practice.
引用
收藏
页数:8
相关论文
共 41 条
  • [1] Risk of dementia in Parkinson's disease - A community-based, prospective study
    Aarsland, D
    Andersen, K
    Larsen, JP
    Lolk, A
    Nielsen, H
    Kragh-Sorensen, P
    [J]. NEUROLOGY, 2001, 56 (06) : 730 - 736
  • [2] Aarsland D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00280-3
  • [3] The epidemiology of dementia associated with Parkinson disease
    Aarsland, Dag
    Kurz, Martin Wilhelm
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 289 (1-2) : 18 - 22
  • [4] Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
    Anheim, M.
    Elbaz, A.
    Lesage, S.
    Durr, A.
    Condroyer, C.
    Viallet, F.
    Pollak, P.
    Bonaiti, B.
    Bonaiti-Pellie, C.
    Brice, A.
    [J]. NEUROLOGY, 2012, 78 (06) : 417 - 420
  • [5] The Impact of Type 2 Diabetes in Parkinson's Disease
    Athauda, Dilan
    Evans, James
    Wernick, Anna
    Virdi, Gurvir
    Choi, Minee L.
    Lawton, Michael
    Vijiaratnam, Nirosen
    Girges, Christine
    Ben-Shlomo, Yoav
    Ismail, Khalida
    Morris, Huw
    Grosset, Donald
    Foltynie, Thomas
    Gandhi, Sonia
    [J]. MOVEMENT DISORDERS, 2022, 37 (08) : 1612 - 1623
  • [6] Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
    Blesa, Javier
    Foffani, Guglielmo
    Dehay, Benjamin
    Bezard, Erwan
    Obeso, Jose A.
    [J]. NATURE REVIEWS NEUROSCIENCE, 2022, 23 (02) : 115 - 128
  • [7] Development and Validation of a Prognostic Model for Cognitive Impairment in Parkinson's Disease With REM Sleep Behavior Disorder
    Chen, Fangzheng
    Li, Yuanyuan
    Ye, Guanyu
    Zhou, Liche
    Bian, Xiaolan
    Liu, Jun
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [8] Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture
    Chia, Ruth
    Sabir, Marya S.
    Bandres-Ciga, Sara
    Saez-Atienzar, Sara
    Reynolds, Regina H.
    Gustavsson, Emil
    Walton, Ronald L.
    Ahmed, Sarah
    Viollet, Coralie
    Ding, Jinhui
    Makarious, Mary B.
    Diez-Fairen, Monica
    Portley, Makayla K.
    Shah, Zalak
    Abramzon, Yevgeniya
    Hernandez, Dena G.
    Blauwendraat, Cornelis
    Stone, David J.
    Eicher, John
    Parkkinen, Laura
    Ansorge, Olaf
    Clark, Lorraine
    Honig, Lawrence S.
    Marder, Karen
    Lemstra, Afina
    St George-Hyslop, Peter
    Londos, Elisabet
    Morgan, Kevin
    Lashley, Tammaryn
    Warner, Thomas T.
    Jaunmuktane, Zane
    Galasko, Douglas
    Santana, Isabel
    Tienari, Pentti J.
    Myllykangas, Liisa
    Oinas, Minna
    Cairns, Nigel J.
    Morris, John C.
    Halliday, Glenda M.
    Van Deerlin, Vivianna M.
    Trojanowski, John Q.
    Grassano, Maurizio
    Calvo, Andrea
    Mora, Gabriele
    Canosa, Antonio
    Floris, Gianluca
    Bohannan, Ryan C.
    Brett, Francesca
    Gan-Or, Ziv
    Geiger, Joshua T.
    [J]. NATURE GENETICS, 2021, 53 (03) : 294 - +
  • [9] Survival and dementia in GBA-associated Parkinson's disease: The mutation matters
    Cilia, Roberto
    Tunesi, Sara
    Marotta, Giorgio
    Cereda, Emanuele
    Siri, Chiara
    Tesei, Silvana
    Zecchinelli, Anna L.
    Canesi, Margherita
    Mariani, Claudio B.
    Meucci, Nicoletta
    Sacilotto, Giorgio
    Zini, Michela
    Barichella, Michela
    Magnani, Corrado
    Duga, Stefano
    Asselta, Rosanna
    Solda, Giulia
    Seresini, Agostino
    Seia, Manuela
    Pezzoli, Gianni
    Goldwurm, Stefano
    [J]. ANNALS OF NEUROLOGY, 2016, 80 (05) : 662 - 673
  • [10] Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease
    D'Souza, Tyrra
    Rajkumar, Anto P.
    [J]. ACTA NEUROPSYCHIATRICA, 2020, 32 (01): : 10 - 22